The company added that ISIS-SOD1Rx is part of its strategic collaboration with Biogen to discover and develop antisense drugs
to treat neurological diseases, including ALS, a rare, fatal neurodegenerative disorder.
Isis Pharmaceuticals, a company involved in the discovery and growth of antisense drugs
using novel drug discovery platform, announced that it has gained a $3 million milestone payment from GlaxoSmithKline (GSK) concerning to start up of a natural history study, which will support the advancement of one of the alliance programmes.
The patent claims broadly cover antisense drugs
with "chimeric" or "gapmer" structures, including Isis' proprietary second-generation structures and the compositions of numerous other antisense compounds.
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE(R) antisense drugs
Isis and Lilly will continue to advance antisense drugs
identified during the previous collaboration, and continue their efforts to develop and refine antisense technologies.
Inhalation could be used as the entrance of antisense drugs
into the body.
The promise of antisense drugs
lies in the theory that they work on a specific target disease without causing significant side effects.
This alliance combines Isis' expertise in antisense technology to evaluate potential neurological targets and discover antisense drugs
with Biogen's capability to develop therapies for neurological disorders.
Second-generation antisense drugs
offer greater potency, enhanced tolerability, and improved dosing convenience compared to first-generation antisense drugs
are short, chemically-modified RNA-like and DNA-like molecules that scientists design to complement a small, specific segment of messenger RNA.
a San Diego-based biotechnology company, to develop so-called antisense drugs
to block the activity of bcl-2.